dyskinesia

H. Lundbeck A/S initiates a phase I study of a potential new treatment of Parkinson’s disease

Lu AF28996 is the third compound added to Lundbeck's clinical development pipeline in 2018. VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck…

6 years ago

H. Lundbeck A/S to acquire Prexton Therapeutics BV for EUR 100 million upfront and up to EUR 805 million in development and sales milestones paid later

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805…

6 years ago